Market Overview

UPDATE: Morgan Stanley Initiates Alkermes at Equal-Weight on Commercialization Visibility

Related ALKS
Alkermes PLC Announces Completion Of Patient Enrollment In Phase 2 Study Of ALKS 3831, A Novel, Broad-Spectrum Oral Antipsychotic
US Stock Futures Rise Ahead Of Economic Data

Morgan Stanley initiated coverage on Alkermes (NASDAQ: ALKS) with an Equal-weight rating and a $21 price target.

Morgan Stanley commented, "We have high regard for management, and see pipeline drug 5461 (depression) as intriguing. But we are cautious on commercialization prospects for 9070 (schizophrenia), and believe the stock valuation appropriately discounts growth outlook … ALKS trades at EV/EBITDA of 21x F13E and 15x F16E (we are focused on F16 because key launches are expected by then). We project 8-yr CAGR (F13-F21E) revenue growth of 6% and EPS growth of 13%. Note ALKS's low tax rate (est. mid-teens long-term) helps justify above average EBITDA multiple."

Alkermes closed at $19.97 on Monday.

Latest Ratings for ALKS

DateFirmActionFromTo
Apr 2014Mizuho SecuritiesUpgradesNeutralBuy
Apr 2014Credit SuisseInitiates Coverage onOutperform
Jan 2014Goldman SachsMaintainsNeutral

View More Analyst Ratings for ALKS
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (ALKS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters